Starpharma Holdings Limited (SPHRF)
| Market Cap | 273.64M +667.0% |
| Revenue (ttm) | 8.76M +116.5% |
| Net Income | -5.16M |
| EPS | -0.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 315.91 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 480 |
| Open | 0.4747 |
| Previous Close | n/a |
| Day's Range | 0.4747 - 0.4747 |
| 52-Week Range | 0.1630 - 0.5821 |
| Beta | 0.77 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 1, 2026 |
About Starpharma Holdings
Starpharma Holdings Limited is a global biopharmaceutical firm dedicated to the investigation, advancement, and marketing of its proprietary dendrimer-based products for pharmaceutical, life science, and other diverse applications. Among its commercialized offerings is VivaGel, an antibiotic-free therapy designed for both preventing and managing bacterial vaginosis. The company's pipeline also features the VivaGel antiviral condom and VIRALEZE, an antiviral nasal spray. A cornerstone of Starpharma's innovation is its Dendrimer Enhanced Product ... [Read more]
Financial Performance
In fiscal year 2026, Starpharma Holdings's revenue was 12.67 million, an increase of 116.55% compared to the previous year's 5.85 million. Losses were -7.47 million, -25.28% less than in 2025.
Financial numbers in AUD Financial StatementsNews
Starpharma presents compelling data in Prostate Cancer at ESMO
MELBOURNE, Australia, Sept. 12, 2022 /PRNewswire/ -- Cabazitaxel (Jevtana, Sanofi) is a market leading chemotherapy for the treatment of advanced prostate cancer (mCRPC).
Starpharma signs new DEP® agreement with MSD
MELBOURNE, Australia , Aug. 10, 2022 /PRNewswire/ -- Australian biotechnology company Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp & D...
Starpharma releases positive DEP® phase 2 interim results in prostate cancer
MELBOURNE, Australia, Nov. 26, 2021 /PRNewswire/ -- Melbourne biotech company Starpharma today announced positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® c...
US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments
MELBOURNE, Australia, Sept. 15, 2021 /PRNewswire/ -- DEP® cabazitaxel is a proprietary nanoparticle version of leading prostate cancer drug cabazitaxel (Jevtana®), which had global sales of US$536 mil...
Starpharma signs DEP® ADC Research Agreement with MSD
MELBOURNE, Australia, Feb. 11, 2021 /PRNewswire/ -- Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that is has signed a Research Agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth...
Starpharma to Webcast Live at Life Sciences Investor Forum September 17th
Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com Company invites individual and...
Starpharma’s SPL7013 COVID-19 Nasal Spray Virucidal Against SARS-CoV-2
MELBOURNE, Australia--(BUSINESS WIRE)--Starpharma’s SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2
Starpharma creates slow release soluble DEP remdesivir nanoparticle
MELBOURNE, Australia--(BUSINESS WIRE)--Starpharma creates slow release soluble DEP® remdesivir nanoparticle
Starpharma SPL7013 Nasal Spray for COVID-19 – Development Update
MELBOURNE, Australia--(BUSINESS WIRE)--Starpharma SPL7013 nasal spray for COVID-19 – development update